BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...Roche (SIX:ROG; OTCQX:RHHBY) markets Avastin, an anti-VEGF mAb. Protalix’s Fabry disease therapy improves kidney function Protalix BioTherapeutics Inc....
...one year improved the estimated glomerular filtration rate (eGFR) from -5.90 to -1.19 mL/min/1.73 m²/year. Protalix...
...olaparib (AZD2281, KU-0059436, MK-7339) alpha galactosidase, pegunigalsidase alfa (CHF 6657; PRX-102) elafibranor (GFT505) [MERGED] AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit...
BioCentury | Aug 22, 2019
Distillery Therapeutics

TNFR2 agonism for neuropathic pain

...cold allodynia and thermal hyperalgesia and decreased levels of inflammatory markers in the sciatic nerve. Protalix BioTherapeutics Inc....
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...clinical research at the Tesaro Inc. unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Recombinant protein company Protalix BioTherapeutics Inc....
...R&D, will run day-to-day operations and clinical development, respectively, effective immediately. Jonathan Block, Associate Editor Arvinas Inc. Novaremed AG Protalix BioTherapeutics Inc. Verastem...
BioCentury | Jun 7, 2019
Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

...MS Candidate Ozanimod" ). Protalix, Chiesi eyeing accelerated approval for Fabry disease therapy next year Protalix BioTherapeutics Inc....
...pegunigalsidase alfa (PRX-102) AXO-AAV-OPMD (BB-301, papbarna) ozanimod (RPC1063) pretomanid, nitroimidazopyran (PA-824) Sio Gene Therapies Inc. Benitec Biopharma Inc. Chiesi Farmaceutici S.p.A. Mylan N.V. Protalix BioTherapeutics Inc. Vertex...
BioCentury | Jul 23, 2018
Company News

Management tracks: CStone, BMS

...company Gamida Cell Ltd. (Jerusalem, Israel) hired Tzvi Palash as COO. He was COO at Protalix BioTherapeutics Inc....
BioCentury | Jan 12, 2018
Clinical News

Protalix reports interim Phase II data for UC candidate

...plant cell-expressed recombinant tumor necrosis factor receptor 2 (TNFR2) fused to an IgG1 Fc domain. Protalix BioTherapeutics Inc....
...calprotectin levels and pharmacokinetics Status: Interim Phase II data Milestone: Additional Phase II data (1Q18) Allison Johnson OPRX-106 Protalix BioTherapeutics Inc. Tumor...
BioCentury | Oct 20, 2017
Company News

Chiesi licenses Protalix's Fabry's disease candidate

...rights to pegunigalsidase alfa (PRX-102), which is in Phase III testing to treat Fabry's disease. Protalix...
...$25 million in development funding and $320 million in regulatory and commercial milestones, plus royalties. Protalix...
...Sanofi (Euronext:SAN; NYSE:SNY). PRX-102 is a plant cell-expressed recombinant form of human alpha galactosidase A. Protalix BioTherapeutics Inc....
BioCentury | Oct 18, 2017
Company News

Chiesi, Protalix in ex-U.S. Fabry's deal

...pegunigalsidase alfa ( PRX-102 ), which is in Phase III testing to treat Fabry's disease. Protalix...
...$25 million in development funding and $320 million in regulatory and commercial milestones, plus royalties. Protalix...
...PRX-102 is a plant cell-expressed recombinant form of human alpha galactosidase A . On Wednesday, Protalix...
BioCentury | Aug 4, 2017
Company News

CVS unveils changes to 2018 formulary

...Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc....
BioCentury | Aug 3, 2017
Politics & Policy

CVS unveils changes to 2018 formulary

...Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc....
Items per page:
1 - 10 of 186
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...Roche (SIX:ROG; OTCQX:RHHBY) markets Avastin, an anti-VEGF mAb. Protalix’s Fabry disease therapy improves kidney function Protalix BioTherapeutics Inc....
...one year improved the estimated glomerular filtration rate (eGFR) from -5.90 to -1.19 mL/min/1.73 m²/year. Protalix...
...olaparib (AZD2281, KU-0059436, MK-7339) alpha galactosidase, pegunigalsidase alfa (CHF 6657; PRX-102) elafibranor (GFT505) [MERGED] AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit...
BioCentury | Aug 22, 2019
Distillery Therapeutics

TNFR2 agonism for neuropathic pain

...cold allodynia and thermal hyperalgesia and decreased levels of inflammatory markers in the sciatic nerve. Protalix BioTherapeutics Inc....
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...clinical research at the Tesaro Inc. unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Recombinant protein company Protalix BioTherapeutics Inc....
...R&D, will run day-to-day operations and clinical development, respectively, effective immediately. Jonathan Block, Associate Editor Arvinas Inc. Novaremed AG Protalix BioTherapeutics Inc. Verastem...
BioCentury | Jun 7, 2019
Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

...MS Candidate Ozanimod" ). Protalix, Chiesi eyeing accelerated approval for Fabry disease therapy next year Protalix BioTherapeutics Inc....
...pegunigalsidase alfa (PRX-102) AXO-AAV-OPMD (BB-301, papbarna) ozanimod (RPC1063) pretomanid, nitroimidazopyran (PA-824) Sio Gene Therapies Inc. Benitec Biopharma Inc. Chiesi Farmaceutici S.p.A. Mylan N.V. Protalix BioTherapeutics Inc. Vertex...
BioCentury | Jul 23, 2018
Company News

Management tracks: CStone, BMS

...company Gamida Cell Ltd. (Jerusalem, Israel) hired Tzvi Palash as COO. He was COO at Protalix BioTherapeutics Inc....
BioCentury | Jan 12, 2018
Clinical News

Protalix reports interim Phase II data for UC candidate

...plant cell-expressed recombinant tumor necrosis factor receptor 2 (TNFR2) fused to an IgG1 Fc domain. Protalix BioTherapeutics Inc....
...calprotectin levels and pharmacokinetics Status: Interim Phase II data Milestone: Additional Phase II data (1Q18) Allison Johnson OPRX-106 Protalix BioTherapeutics Inc. Tumor...
BioCentury | Oct 20, 2017
Company News

Chiesi licenses Protalix's Fabry's disease candidate

...rights to pegunigalsidase alfa (PRX-102), which is in Phase III testing to treat Fabry's disease. Protalix...
...$25 million in development funding and $320 million in regulatory and commercial milestones, plus royalties. Protalix...
...Sanofi (Euronext:SAN; NYSE:SNY). PRX-102 is a plant cell-expressed recombinant form of human alpha galactosidase A. Protalix BioTherapeutics Inc....
BioCentury | Oct 18, 2017
Company News

Chiesi, Protalix in ex-U.S. Fabry's deal

...pegunigalsidase alfa ( PRX-102 ), which is in Phase III testing to treat Fabry's disease. Protalix...
...$25 million in development funding and $320 million in regulatory and commercial milestones, plus royalties. Protalix...
...PRX-102 is a plant cell-expressed recombinant form of human alpha galactosidase A . On Wednesday, Protalix...
BioCentury | Aug 4, 2017
Company News

CVS unveils changes to 2018 formulary

...Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc....
BioCentury | Aug 3, 2017
Politics & Policy

CVS unveils changes to 2018 formulary

...Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc....
Items per page:
1 - 10 of 186